Search
Search
About
Log in
Join
Experiences with
Idelalisib
Posts
Communities
142 public posts
Filter results
Early use of Ibrutinib or is W&W still a needed strategy?
The question of Early Front-line use for kinase inhibition drugs like Ibrutinib or
Idelalisib
is not a slam-dunk based solely on their extraordinary efficacy to date.
The question of Early Front-line use for kinase inhibition drugs like Ibrutinib or
Idelalisib
is not a slam-dunk based solely on their extraordinary efficacy to date.
ThreeWs
in
CLL Support
10 years ago
iwCLL 2013: Dr. Jeff Sharman Discusses Two Issues: 17p deletion and Residual Disease in CLL
Sharman to spectate on the issues of 17 p deletion and of the importance of residual disease with ibrutinib and
idelalisib
. See http://bkoffman.blogspot.com This is a very interesting segment for me. Thanks to all who sent well wishes and prayers. While I am not yet well, I am getting better.
Sharman to spectate on the issues of 17 p deletion and of the importance of residual disease with ibrutinib and
idelalisib
. See http://bkoffman.blogspot.com This is a very interesting segment for me. Thanks to all who sent well wishes and prayers. While I am not yet well, I am getting better.
bkoffman
CLL CURE Hero
in
CLL Support
10 years ago
Dr Peter Hillmen of Leeds, UK discusses the place for Idelalisib in CLL treatment (Patient Power Video)
In this short video taken at iwCLL Collogne Germany, Andrew Schorr interviews Dr Hillmen: [i]"As a full slate of new treatments for CLL show promise, one approach--with a drug called
idelalisib
--is to inhibit the PI3k pathway that is active in CLL. Dr.
In this short video taken at iwCLL Collogne Germany, Andrew Schorr interviews Dr Hillmen: [i]"As a full slate of new treatments for CLL show promise, one approach--with a drug called
idelalisib
--is to inhibit the PI3k pathway that is active in CLL. Dr.
AussieNeil
Administrator
in
CLL Support
11 years ago
Want to take advantage of all our features? Just log in!
Log in
or
Join
Update on Novel B-Cell Receptor Signaling Inhibitors from NCCN 8th Annual Congress on Hematologic Malignancies
These novel agents include PI3-Kinase (PI3K) inhibitors (eg,
idelalisib
) and Bruton’s tyrosine kinase (BTK) inhibitors (eg, ibrutinib), and are considered a breakthrough for CLL and other B-cell lymphomas.
These novel agents include PI3-Kinase (PI3K) inhibitors (eg,
idelalisib
) and Bruton’s tyrosine kinase (BTK) inhibitors (eg, ibrutinib), and are considered a breakthrough for CLL and other B-cell lymphomas.
AussieNeil
Administrator
in
CLL Support
11 years ago
Late October - Clinical trial update - B + R and Idelalisib - CAL 101
Hey, Well three days in the Day Care centre last week - first for IVIG and then the fourth round of two day chemo infusions. Both went reasonably well, with the minor frustrations of "red tape & paperwork". Although I was able to drive home after all three visits, I have felt lathargic over the weekend
Hey, Well three days in the Day Care centre last week - first for IVIG and then the fourth round of two day chemo infusions. Both went reasonably well, with the minor frustrations of "red tape & paperwork". Although I was able to drive home after all three visits, I have felt lathargic over the weekend
MartyR
in
CLL Support
11 years ago
ASH 2013 - Dr Sharman's abstracts
The B cell receptor signaling pathway involves a sequence of enzymes that start with Syk (fostamatanib, GS-9973), goes to BTK (ibrutinib and CC-292), then on to PI3K (
idelalisib
). Antibody drug conjugates are another favorite topic of mine.
The B cell receptor signaling pathway involves a sequence of enzymes that start with Syk (fostamatanib, GS-9973), goes to BTK (ibrutinib and CC-292), then on to PI3K (
idelalisib
). Antibody drug conjugates are another favorite topic of mine.
AussieNeil
Administrator
in
CLL Support
11 years ago
Dr Sharman's thoughts on the race for FDA Approval for Obinituzumab, Ibrutinib and Idelalisib
Following Gilead's announcement regarding
Idelalisib
: https://healthunlocked.com/cllsupport/posts/130204565/gilead-to-stop-phase-3-study-116-of-
idelalisib
-in-chronic-lymphocytic-leukemia-early-because-of-positive-risk-benefit Dr Sharman summarises where things stand with Obinituzumab, Ibrutinib and
Idelalisib
Following Gilead's announcement regarding
Idelalisib
: https://healthunlocked.com/cllsupport/posts/130204565/gilead-to-stop-phase-3-study-116-of-
idelalisib
-in-chronic-lymphocytic-leukemia-early-because-of-positive-risk-benefit Dr Sharman summarises where things stand with Obinituzumab, Ibrutinib and
Idelalisib
AussieNeil
Administrator
in
CLL Support
11 years ago
October - Clinical trial mini-update - B + R and Idelalisib - CAL 101
Doctor strongly suspects that the blood results and lymph node reduction are due to me receiving the trial
Idelalisib
tablet and not the Placebo ! I hope everyone can find their own positive solution to their situation! Marty
Doctor strongly suspects that the blood results and lymph node reduction are due to me receiving the trial
Idelalisib
tablet and not the Placebo ! I hope everyone can find their own positive solution to their situation! Marty
MartyR
in
CLL Support
11 years ago
iwCLL 2013: Dr. Jan Burger on the Role of the Micro-Environment in CLL
While this is basic bench science, it is critical to understanding how many of the novel therapies such as
idelalisib
and ibrutinib work and how difficult it can be for traditional therapies to get rid of CLL deep in the nodes and marrow.
While this is basic bench science, it is critical to understanding how many of the novel therapies such as
idelalisib
and ibrutinib work and how difficult it can be for traditional therapies to get rid of CLL deep in the nodes and marrow.
bkoffman
CLL CURE Hero
in
CLL Support
11 years ago
September - Clinical trial update - B + R and Idelalisib - CAL 101
The Company further added that it plans to file for regulatory approval of
idelalisib
in the European Union in Q4 2013 So best wishes to all for a great weekend ! Marty
The Company further added that it plans to file for regulatory approval of
idelalisib
in the European Union in Q4 2013 So best wishes to all for a great weekend ! Marty
MartyR
in
CLL Support
11 years ago
August - Clinical trial update - B + R and Idelalisib - CAL 101
Hey CLLers Unfortunately my second B + R infusions in this clinical trial were delayed by a week due to a query raised by Pharmacy - compounded by a lack of space in the Day Care Unit. Contact was made with the Clinical Trial Company and they have agreed to the delay of my B + R chemotherapy - but I
Hey CLLers Unfortunately my second B + R infusions in this clinical trial were delayed by a week due to a query raised by Pharmacy - compounded by a lack of space in the Day Care Unit. Contact was made with the Clinical Trial Company and they have agreed to the delay of my B + R chemotherapy - but I
MartyR
in
CLL Support
11 years ago
IVIG & Clinical Trial with B + R -- Idelalisib (GS-1101) OR CAL 101 Study (III)
So yesterday - Monday 29th - 11 days after my first chemo B + R - I had an infusion of IVIG to help my deficient immune system. I did not appear to suffer any side effects - besides generally these are stated as being "mild, transient & self-limiting." For those who are interested in facts, the Hospital
So yesterday - Monday 29th - 11 days after my first chemo B + R - I had an infusion of IVIG to help my deficient immune system. I did not appear to suffer any side effects - besides generally these are stated as being "mild, transient & self-limiting." For those who are interested in facts, the Hospital
MartyR
in
CLL Support
11 years ago
July 2013 Trial with B + R -- Idelalisib (GS-1101) OR CAL 101 Study (III)
Live from hospital bed -->> my first cycle of Infused Bendamustine and Rituximab appears to have gone well with no side effects - except tiredness - at this stage! I have literally the last drips of Bendamustine going into my veins! I've been told I am discharged from hospital and so home for the weekend
Live from hospital bed -->> my first cycle of Infused Bendamustine and Rituximab appears to have gone well with no side effects - except tiredness - at this stage! I have literally the last drips of Bendamustine going into my veins! I've been told I am discharged from hospital and so home for the weekend
MartyR
in
CLL Support
11 years ago
Update July 2013 Trial with B + R -- Idelalisib (GS-1101) OR CAL 101 Study (III)
Hey, - its Monday morning here - three days after completing my first round of treatment. In general I feel reasonable - a bit tired and lethargic - but none of the more unpleasant side effects - SO FAR!! The infusions went well over the two days and whilst my Temperature, BP and Pulse Rate rose and
Hey, - its Monday morning here - three days after completing my first round of treatment. In general I feel reasonable - a bit tired and lethargic - but none of the more unpleasant side effects - SO FAR!! The infusions went well over the two days and whilst my Temperature, BP and Pulse Rate rose and
MartyR
in
CLL Support
11 years ago
UK Clinical Trial with B + R -- Idelalisib (GS-1101) OR CAL 101 Study (III)
Hey, I believe that I have been accepted for this Clinical Trial, starting in July '13 - I wonder if anyone else in the UK (or the world! ) would like to share the "journey / experience" with me over the forthcoming months - even better if your trial also in Birmingham UK !! Regards, MartyR )----<<<
Hey, I believe that I have been accepted for this Clinical Trial, starting in July '13 - I wonder if anyone else in the UK (or the world! ) would like to share the "journey / experience" with me over the forthcoming months - even better if your trial also in Birmingham UK !! Regards, MartyR )----<<<
MartyR
in
CLL Support
11 years ago
Dr Susan O'brien and Dr Kanti Rai
While the ‘ news ‘ is not truly new, it is laid out in simple terms that
idelalisib
will give a 97% response rate. That is a truly amazing figure and fantastic news.
While the ‘ news ‘ is not truly new, it is laid out in simple terms that
idelalisib
will give a 97% response rate. That is a truly amazing figure and fantastic news.
Kwenda
in
CLL Support
11 years ago
Dr Sharman blogs on Cure for CLL & NHL?.... or just better control?
http://www.cll-nhl.com/2013/06/cure-for-cll-nhl-or-just-better-control.html I'm eagerly awaiting his mooted future topic on death by neglect (of CLL cells), where he'll cover how ibrutinib and
idelalisib
flush CLL cells out of the bone marrow and lymph nodes into the peripheral blood where they
http://www.cll-nhl.com/2013/06/cure-for-cll-nhl-or-just-better-control.html I'm eagerly awaiting his mooted future topic on death by neglect (of CLL cells), where he'll cover how ibrutinib and
idelalisib
flush CLL cells out of the bone marrow and lymph nodes into the peripheral blood where they
AussieNeil
Administrator
in
CLL Support
11 years ago
Idelalisib Phase III Clinical Trial for previously treated CLL
term=
IDELALISIB
&rank=5&show_locs=Y#locn
term=
IDELALISIB
&rank=5&show_locs=Y#locn
Cllcanada
Top Poster CURE Hero
in
CLL Support
11 years ago
Winners And Losers in CLL at ASCO '13 - a marketing strategy consultant's perspective
He covers in particular how the new drugs by Gilead Sciences (
idelalisib
), Roche (Obinutuzumab - GA101), Infinity Pharmaceuticals (IPI-145), AbbVie (with Roche) (ABT-199), Pharmacyclics and Johnson & Johnson (Ibrutinib) fared in their ASCO presentations and which companies with CLL drug development in
He covers in particular how the new drugs by Gilead Sciences (
idelalisib
), Roche (Obinutuzumab - GA101), Infinity Pharmaceuticals (IPI-145), AbbVie (with Roche) (ABT-199), Pharmacyclics and Johnson & Johnson (Ibrutinib) fared in their ASCO presentations and which companies with CLL drug development in
AussieNeil
Administrator
in
CLL Support
11 years ago
New PI3K-delta Inhibitor Prolongs Survival in Chronic Lymphocytic Leukaemia
The substantial clinical activity of
idelalisib
that we observed justifies its further clinical development in CLL,” said Jennifer R. Brown, MD, PhD, director of the Chronic Lymphocytic Leukemia center at Dana-Farber Cancer Institute in Massachusetts and lead author of the study.
The substantial clinical activity of
idelalisib
that we observed justifies its further clinical development in CLL,” said Jennifer R. Brown, MD, PhD, director of the Chronic Lymphocytic Leukemia center at Dana-Farber Cancer Institute in Massachusetts and lead author of the study.
Cllcanada
Top Poster CURE Hero
in
CLL Support
11 years ago
1
...
6
7
8
Next page
Filter results
Clear filters
Posted in
All communities
CLL Support
132 results
Non Hodgkin's Lymphoma Friends
6 results
Advanced Prostate Cancer
1 result
View top 10 communities
Sort by
Most Relevant
Newest